These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26684614)

  • 1. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J; Seabrook J; Fulford A; Rajakumar I
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
    Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
    Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Lilleby K; Garcia P; Gooley T; McDonnnell P; Taber R; Holmberg L; Maloney DG; Press OW; Bensinger W
    Bone Marrow Transplant; 2006 Jun; 37(11):1031-5. PubMed ID: 16633359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
    J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation.
    Bhatt V; Vendrell N; Nau K; Crumb D; Roy V
    J Oncol Pharm Pract; 2010 Sep; 16(3):195-204. PubMed ID: 19910393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
    de Paula Eduardo F; Bezinelli LM; da Graça Lopes RM; Nascimento Sobrinho JJ; Hamerschlak N; Correa L
    Hematol Oncol; 2015 Sep; 33(3):152-8. PubMed ID: 24519448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
    McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
    Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation.
    Nakagaki M; Kennedy GA; Gavin NC; Clavarino A; Whitfield K
    Support Care Cancer; 2022 Nov; 30(11):9141-9149. PubMed ID: 36008731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study.
    Lu Y; Zhu X; Ma Q; Wang J; Jiang P; Teng S; Zhou L; Wu D; Wang H
    Support Care Cancer; 2020 Apr; 28(4):1747-1754. PubMed ID: 31302767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
    Vokurka S; Bystricka E; Scudlova J; Mazur E; Visokaiova M; Vasilieva E; Brandejsova R; Chvojkova I; Vrabcova M; Vitkova J; Mjartanova D; Vodickova M; Bockova J; Streinerova K
    Eur J Oncol Nurs; 2011 Dec; 15(5):508-12. PubMed ID: 21310656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
    Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
    Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.
    Mori T; Yamazaki R; Aisa Y; Nakazato T; Kudo M; Yashima T; Kondo S; Ikeda Y; Okamoto S
    Support Care Cancer; 2006 Apr; 14(4):392-5. PubMed ID: 16633843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
    Waśko-Grabowska A; Rzepecki P; Oborska S; Barzał J; Gawroński K; Młot B; Szczylik C
    Transplant Proc; 2011 Oct; 43(8):3111-3. PubMed ID: 21996239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryotherapy effect on oral mucositis severity among recipients of bone marrow transplantation: a literature review.
    Tayyem AQ
    Clin J Oncol Nurs; 2014 Aug; 18(4):E84-7. PubMed ID: 25095309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the adverse effects of melphalan formulations.
    Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early salivary changes in multiple myeloma patients undergoing autologous HSCT.
    van Leeuwen S; Proctor GB; Potting C; Ten Hoopen S; van Groningen L; Bronkhorst EM; Blijlevens N; Huysmans M
    Oral Dis; 2018 Sep; 24(6):972-982. PubMed ID: 29637662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.